• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MDxHealth SA (Amendment)

    3/17/23 4:19:19 PM ET
    $MDXH
    Medical Specialities
    Health Care
    Get the next $MDXH alert in real time by email
    SC 13G/A 1 ea175333-13ga1biovest_mdx.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    MDxHealth SA

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    58286E102 **

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 58286E102 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Capital Market under the symbol “MDXH.” Each American Depositary Share represents the right to receive ten Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

    (Continued on following pages)

     

     

     

     

     

     

    CUSIP No. 58286E102

     

    1.

    NAME OF REPORTING PERSONS

     

    RMM, S.A.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    11,923,587 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    11,923,587(1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,923,587(1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.4%

    12.

    TYPE OF REPORTING PERSON

     

    FI

     

    (1)Consists of 11,090,257 ordinary shares and 83,333 American Depositary Shares held by Biovest NV (“Biovest”). The Reporting Person is the sole owner of Biovest and pursuant to an understanding with Biovest, decisions relating to the voting and dispositive power of the shares are shared between Biovest and the Reporting Person’s Board of Directors (the “Board”). Voting and investment power over the shares managed by the Board is exercised jointly by more than three natural persons and voting and disposition decisions require the approval of a majority of such persons. Accordingly, no single natural person has a controlling decision and no individual director of the Reporting Person should be deemed to be a beneficial owner of the shares.

     

    2

     

     

    CUSIP No. 58286E102

     

    1.

    NAME OF REPORTING PERSONS

     

    Biovest NV

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Belgium

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    11,923,587 (2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    11,923,587 (2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,923,587 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.4%

    12.

    TYPE OF REPORTING PERSON

     

    FI

     

    (2)Consists of 11,090,257 ordinary shares and 83,333 American Depositary Shares held by the Reporting Person. Pursuant to an understanding with RMM, S.A., decisions relating to the voting and dispositive power of the shares are shared between the Reporting Person and RMM, S.A.

     

    3

     

     

    Item 1(a).Name of Issuer:

     

    MDxHealth SA

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    CP Business Center

    Zone Industrielle des Hauts-Sarts

    4040 Herstal, Belgium

     

    Item 2(a).Name of Person Filing:

     

    RMM, S.A.

    Biovest NV

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    RMM, S.A. ‒ 19-21 Route D’Arlon, L-8009 Strassen, Luxembourg

    Biovest NV ‒ Karel Van De Woestijnestraat 3, 9000 Gent, Belgium

     

    Item 2(c).Citizenship:

     

    RMM, S.A. ‒ Luxembourg

    Biovest NV ‒ Belgium

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary shares, no par value

     

    Item 2(e).CUSIP Number:

     

    58286E102

     

    There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 58286E102 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Capital Market under the symbol “MDXH.” Each American Depositary Share represents the right to receive ten Ordinary Shares.

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned: See responses to Item 9 on the attached cover pages.

     

    (b)Percent of class: See responses to Item 1 on the attached cover pages.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to direct the vote: See responses to Item 5 on the attached cover pages.

     

    4

     

     

    (ii)Shared power to direct the vote: See responses to Item 6 on the attached cover pages.

     

    (iii)Sole power to dispose or to direct the disposition of: See responses to Item 7 on the attached cover pages.

     

    (iv)Shared power to dispose or to direct the disposition of: See responses to Item 8 on the attached cover pages.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not applicable.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 17, 2023

     

      RMM, S.A.
         
      /s/ Rudi Mariën
      Name: Rudi Mariën
      Title: Director
         
      /s/ Hoolants Ingrid
      Name:  Hoolants Ingrid
      Title: Director
         
      BIOVEST NV
         
      /s/ Stefan Mariën
      Name: RMM Services, represented by Stefan Mariën
      Title: Director

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    [Signature page to Schedule 13G]

     

     

    6

     

    Get the next $MDXH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDXH

    DatePrice TargetRatingAnalyst
    10/31/2024$7.00Buy
    Lake Street
    5/31/2023$7.00Outperform
    TD Cowen
    7/18/2022$18.00Outperform
    Oppenheimer
    More analyst ratings

    $MDXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on MDxHealth SA with a new price target

      Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00

      10/31/24 8:59:17 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • TD Cowen initiated coverage on MDxHealth SA with a new price target

      TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00

      5/31/23 7:34:28 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Oppenheimer resumed coverage on MDxHealth SA with a new price target

      Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00

      7/18/22 9:23:47 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mvm Partners, Llc bought $4,000,000 worth of shares (1,000,000 units at $4.00)

      4 - MDxHealth SA (0001872529) (Issuer)

      2/28/23 4:22:02 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo

      2/26/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

                  Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie

      7/8/24 8:00:00 AM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Resignation of Board Member

      Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor

      2/16/24 8:45:00 AM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Financials

    Live finance-specific insights

    See more
    • MDxHealth Reports Q1-2025 Results

      Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa

      5/14/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth to Release First Quarter 2025 Financial Results on May 14

      Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800

      4/30/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo

      2/26/25 4:00:00 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    SEC Filings

    See more
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      5/14/25 4:05:22 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by MDxHealth SA

      6-K - MDxHealth SA (0001872529) (Filer)

      5/2/25 4:05:03 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by MDxHealth SA

      20-F - MDxHealth SA (0001872529) (Filer)

      3/31/25 4:02:30 PM ET
      $MDXH
      Medical Specialities
      Health Care

    $MDXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      11/14/24 3:15:43 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MDxHealth SA

      SC 13D/A - MDxHealth SA (0001872529) (Subject)

      10/28/24 2:52:50 PM ET
      $MDXH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by MDxHealth SA

      SC 13G - MDxHealth SA (0001872529) (Subject)

      10/4/24 5:14:19 PM ET
      $MDXH
      Medical Specialities
      Health Care